Vienne

Researchers are evaluating the effectiveness of a low-protein diet (LPD) using specially developed low-protein foods (FLAVIS products) compared to a standard low-protein diet without these foods in patients with chronic kidney disease (CKD) stages 3A to 5 who are not on dialysis. The study follows recommendations from the KDOQI 2020 clinical practice guideline, which suggests restricting protein intake to reduce the risk of end-stage renal disease and improve quality of life. The FLAVIS products are designed to help patients achieve nutritional goals more easily while following a low-protein diet. Participants are divided into groups where one group receives FLAVIS products alongside their diet follow-up, while the other group follows the low-protein diet without these products. The study aims to monitor protein intake over a 12-month period to assess how effective the FLAVIS products are in facilitating adherence to the diet and meeting protein intake targets. During the study, participants will attend scheduled visits and complete diet records and self-administered questionnaires to track their adherence and nutritional status. Researchers will measure protein intake as the primary outcome after 12 months. Participants must be motivated to follow a low-protein diet and have good nutritional status at the start. Safety monitoring includes assessing any adverse effects and ensuring participants can provide blood samples and perform 24-hour urine collections as required.